Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 146.90
-4.10 (-2.72%)
Apr 20, 2026, 4:08 PM HKT
Akeso Employees
Akeso had 3,761 employees as of December 31, 2025. The number of employees increased by 726 or 23.92% compared to the previous year.
Employees
3,761
Change
726
Growth
23.92%
Revenue / Employee
904.30K HKD
Profits / Employee
-329.32K HKD
Market Cap
135.32B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,761 | 726 | 23.92% |
| Jun 30, 2025 | 3,529 | - | - |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| BeOne Medicines AG | 12,000 |
| Innovent Biologics | 7,502 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| RemeGen | 3,048 |
| Shanghai Junshi Biosciences | 2,903 |
Akeso News
- 10 days ago - China healthcare stocks outgain Hong Kong market as Middle East roils global investments - South China Morning Post
- 11 days ago - Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst - Benzinga
- 13 days ago - Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026 - PRNewsWire
- 24 days ago - Akeso Reports Full-Year 2025 Financial Results - PRNewsWire
- 26 days ago - Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab - PRNewsWire
- 5 weeks ago - Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance - PRNewsWire
- 6 weeks ago - Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results - PRNewsWire
- 2 months ago - Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications - PRNewsWire